Duchenne Muscular Dystrophy Treatment Market Share

APAC Market Statistics

On the basis of geographical analysis, the global Duchenne muscular dystrophy treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is anticipated to account for largest revenue share by 2036, due to high prevalence of musculoskeletal diseases in the region. For instance, according to the World Bank, in India, 51.964% of the total population is male, in 2020. Moreover, the constant development in public healthcare services, backed by rapid economic growth, are anticipated to boost the market growth.

North America Market Analysis

The market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of the high health awareness amongst the population, along with easy access of quality healthcare in the developed nations. Furthermore, rising concerns amongst authorities, regarding rising prevalence of genetic diseases, is also estimated to boost the market growth.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of duchenne muscular dystrophy treatment is assessed at USD 3.41 billion.

Duchenne Muscular Dystrophy Treatment Market size was valued at USD 3.12 billion in 2023 and is expected to exceed USD 13.3 billion by 2036, expanding at over 11.8% CAGR during the forecast period i.e., between 2024-2036. Increasing incidences of DMD, and the emergence of mutation-specific therapies will boost the market growth.

Asia Pacific industry is anticipated to account for largest revenue share by 2036, due to high prevalence of musculoskeletal diseases in the region.

The major players in the market are Eli Lilly and Company, Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., and others.

Duchenne Muscular Dystrophy Treatment Market Share